Latzin 2008.

Methods	Open‐label RCT for 3 indications: (1) suppression therapy for those with chronic P. aeruginosa not experiencing an exacerbation; (2) acute exacerbation in those with chronic P. aeruginosa infection; and (3) eradication of first detection of P. aeruginosa infection.
Participants	127 participants enrolled, of whom 34 were recruited as they had chronic P. aeruginosa infection and were experiencing an acute exacerbation.
Interventions	Intervention 1: IV meropenem 120 mg/kg/day in 3 doses and IV tobramycin 9 ‐ 12 mg/kg/day in 2 doses. Intervention 2: IV ceftazidime 200 ‐ 400 mg/kg/day in 2 or 3 doses and tobramycin 9 ‐ 12 mg/kg/day in 2 doses.
Outcomes	Lung function, adverse effects, microbiology.
Notes	While a subgroup analysis consisting of the 3 indications is described for lung function, data are presented as a whole. Participants could be recruited 2x although this is not described. We shall seek to contact the authors for IPD to reconcile the UoA issues and for data to contribute to a meta‐analysis.